Overview

A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas

Status:
Completed

Trial end date:
2016-03-29

Target enrollment:

Participant gender:

Summary

This study will evaluate the superiority of ulipristal acetate versus placebo for the treatment of abnormal uterine bleeding associated with uterine fibroids

Phase:

Phase 3

Details

Lead Sponsor:

Allergan
Watson Pharmaceuticals

Treatments:

Ulipristal acetate